Immunotherapy with Checkpoint Blockade in the Treatment of Urothelial Carcinoma

Arlene O. Siefker-Radtke, Andrea B. Apolo, Trinity Bivalacqua, Philippe E. Spiess, Peter C. Black

Research output: Contribution to journalReview article

Abstract

Purpose: Although immunotherapy has a long history in the treatment of urothelial carcinoma, its use was limited to intravesical therapy for nonmuscle invasive disease. The development of immune checkpoint blockers for systemic delivery has expanded the application of immunotherapy to advanced metastatic urothelial cancers. Materials and Methods: The PubMed® database was searched for publications regarding immune checkpoint blockers for the treatment of patients with urothelial carcinoma. Relevant congress abstracts were identified through searches of individual congress websites. Results: A summary of the biology and immunology of urothelial carcinoma provides context to aid in discussing key data pertaining to immune checkpoint blockers that are approved and in development. We address immune mediated adverse events that are unique to immunotherapies and review diagnostic tools that may be useful to identify patients who would most benefit from immunotherapy. Conclusions: Immunotherapies for urothelial carcinoma have shown clinical efficacy in select patients as well as a manageable safety profile. Studies are ongoing with the aim of expanding the proof of efficacy in metastatic disease and providing additional treatment options for patients with earlier stages of urothelial carcinoma.

Original languageEnglish (US)
Pages (from-to)1129-1142
Number of pages14
JournalJournal of Urology
Volume199
Issue number5
DOIs
StatePublished - May 1 2018

Fingerprint

Immunotherapy
Carcinoma
Therapeutics
Allergy and Immunology
PubMed
Publications
History
Databases
Safety
Neoplasms

Keywords

  • carcinoma
  • immunotherapy
  • programmed cell death 1 receptor
  • urinary bladder neoplasms

ASJC Scopus subject areas

  • Urology

Cite this

Immunotherapy with Checkpoint Blockade in the Treatment of Urothelial Carcinoma. / Siefker-Radtke, Arlene O.; Apolo, Andrea B.; Bivalacqua, Trinity; Spiess, Philippe E.; Black, Peter C.

In: Journal of Urology, Vol. 199, No. 5, 01.05.2018, p. 1129-1142.

Research output: Contribution to journalReview article

Siefker-Radtke, Arlene O. ; Apolo, Andrea B. ; Bivalacqua, Trinity ; Spiess, Philippe E. ; Black, Peter C. / Immunotherapy with Checkpoint Blockade in the Treatment of Urothelial Carcinoma. In: Journal of Urology. 2018 ; Vol. 199, No. 5. pp. 1129-1142.
@article{9cbb5f21e4d545728b00195068027586,
title = "Immunotherapy with Checkpoint Blockade in the Treatment of Urothelial Carcinoma",
abstract = "Purpose: Although immunotherapy has a long history in the treatment of urothelial carcinoma, its use was limited to intravesical therapy for nonmuscle invasive disease. The development of immune checkpoint blockers for systemic delivery has expanded the application of immunotherapy to advanced metastatic urothelial cancers. Materials and Methods: The PubMed{\circledR} database was searched for publications regarding immune checkpoint blockers for the treatment of patients with urothelial carcinoma. Relevant congress abstracts were identified through searches of individual congress websites. Results: A summary of the biology and immunology of urothelial carcinoma provides context to aid in discussing key data pertaining to immune checkpoint blockers that are approved and in development. We address immune mediated adverse events that are unique to immunotherapies and review diagnostic tools that may be useful to identify patients who would most benefit from immunotherapy. Conclusions: Immunotherapies for urothelial carcinoma have shown clinical efficacy in select patients as well as a manageable safety profile. Studies are ongoing with the aim of expanding the proof of efficacy in metastatic disease and providing additional treatment options for patients with earlier stages of urothelial carcinoma.",
keywords = "carcinoma, immunotherapy, programmed cell death 1 receptor, urinary bladder neoplasms",
author = "Siefker-Radtke, {Arlene O.} and Apolo, {Andrea B.} and Trinity Bivalacqua and Spiess, {Philippe E.} and Black, {Peter C.}",
year = "2018",
month = "5",
day = "1",
doi = "10.1016/j.juro.2017.10.041",
language = "English (US)",
volume = "199",
pages = "1129--1142",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Immunotherapy with Checkpoint Blockade in the Treatment of Urothelial Carcinoma

AU - Siefker-Radtke, Arlene O.

AU - Apolo, Andrea B.

AU - Bivalacqua, Trinity

AU - Spiess, Philippe E.

AU - Black, Peter C.

PY - 2018/5/1

Y1 - 2018/5/1

N2 - Purpose: Although immunotherapy has a long history in the treatment of urothelial carcinoma, its use was limited to intravesical therapy for nonmuscle invasive disease. The development of immune checkpoint blockers for systemic delivery has expanded the application of immunotherapy to advanced metastatic urothelial cancers. Materials and Methods: The PubMed® database was searched for publications regarding immune checkpoint blockers for the treatment of patients with urothelial carcinoma. Relevant congress abstracts were identified through searches of individual congress websites. Results: A summary of the biology and immunology of urothelial carcinoma provides context to aid in discussing key data pertaining to immune checkpoint blockers that are approved and in development. We address immune mediated adverse events that are unique to immunotherapies and review diagnostic tools that may be useful to identify patients who would most benefit from immunotherapy. Conclusions: Immunotherapies for urothelial carcinoma have shown clinical efficacy in select patients as well as a manageable safety profile. Studies are ongoing with the aim of expanding the proof of efficacy in metastatic disease and providing additional treatment options for patients with earlier stages of urothelial carcinoma.

AB - Purpose: Although immunotherapy has a long history in the treatment of urothelial carcinoma, its use was limited to intravesical therapy for nonmuscle invasive disease. The development of immune checkpoint blockers for systemic delivery has expanded the application of immunotherapy to advanced metastatic urothelial cancers. Materials and Methods: The PubMed® database was searched for publications regarding immune checkpoint blockers for the treatment of patients with urothelial carcinoma. Relevant congress abstracts were identified through searches of individual congress websites. Results: A summary of the biology and immunology of urothelial carcinoma provides context to aid in discussing key data pertaining to immune checkpoint blockers that are approved and in development. We address immune mediated adverse events that are unique to immunotherapies and review diagnostic tools that may be useful to identify patients who would most benefit from immunotherapy. Conclusions: Immunotherapies for urothelial carcinoma have shown clinical efficacy in select patients as well as a manageable safety profile. Studies are ongoing with the aim of expanding the proof of efficacy in metastatic disease and providing additional treatment options for patients with earlier stages of urothelial carcinoma.

KW - carcinoma

KW - immunotherapy

KW - programmed cell death 1 receptor

KW - urinary bladder neoplasms

UR - http://www.scopus.com/inward/record.url?scp=85044360121&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85044360121&partnerID=8YFLogxK

U2 - 10.1016/j.juro.2017.10.041

DO - 10.1016/j.juro.2017.10.041

M3 - Review article

C2 - 29113841

AN - SCOPUS:85044360121

VL - 199

SP - 1129

EP - 1142

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 5

ER -